KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Operations: 2009-2025

Historic Cash from Operations for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $178.6 million.

  • Halozyme Therapeutics' Cash from Operations rose 54.80% to $178.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $611.0 million, marking a year-over-year increase of 51.63%. This contributed to the annual value of $479.1 million for FY2024, which is 23.29% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Cash from Operations stood at $178.6 million, which was up 79.11% from $99.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash from Operations ranged from a high of $178.6 million in Q3 2025 and a low of $36.9 million during Q2 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Cash from Operations value was $115.4 million (recorded in 2024), while the average stood at $118.2 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Cash from Operations spiked by 1,900.97% in 2021, and later plummeted by 42.80% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Cash from Operations (Quarterly) stood at $82.5 million in 2021, then declined by 0.08% to $82.5 million in 2022, then increased by 24.14% to $102.4 million in 2023, then surged by 74.36% to $178.5 million in 2024, then surged by 54.80% to $178.6 million in 2025.
  • Its Cash from Operations stands at $178.6 million for Q3 2025, versus $99.7 million for Q2 2025 and $154.2 million for Q1 2025.